Mineralocorticoid receptor (MR) blockers are a class of drugs used in the treatment of essential hypertension and hyperaldosteronism and have antihypertensive effects in patients with low-renin or refractory (resistant) hypertension; these effects improve prognosis in patients with heart failure [1–9]. The gene discussed is NR3C2; the disease is heart failure.